Geron Corp
GERN1.400USD
+0.070+5.26%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
893.70MMarket Cap
LossP/E TTM
More Details of Geron Corp Company
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Geron Corp Info
Ticker SymbolGERN
Company nameGeron Corp
IPO dateJul 31, 1996
CEOSemerjian (Harout)
Number of employees229
Security typeOrdinary Share
Fiscal year-endJul 31
Address919 East Hillsdale Boulevard
CityFOSTER CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94404
Phone16504737700
Websitehttps://www.geron.com/
Ticker SymbolGERN
IPO dateJul 31, 1996
CEOSemerjian (Harout)
Company Executives of Geron Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Robert J. (Bob) Spiegel, M.D.
Dr. Robert J. (Bob) Spiegel, M.D.
Independent Director
Independent Director
188.55K
+3.12%
Dr. Susan M. Molineaux, Ph.D.
Dr. Susan M. Molineaux, Ph.D.
Independent Director
Independent Director
130.53K
--
Mr. Ahmed (Nawawi) Elnawawi
Mr. Ahmed (Nawawi) Elnawawi
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
10.00K
--
Mr. Harout Semerjian
Mr. Harout Semerjian
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Elizabeth G. O'Farrell
Ms. Elizabeth G. O'Farrell
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
--
--
Ms. Shannon T. Odam
Ms. Shannon T. Odam
Chief People Officer, Senior Vice President
Chief People Officer, Senior Vice President
--
--
Mr. John F. Mcdonald
Mr. John F. Mcdonald
Independent Director
Independent Director
--
--
Dr. Faye Feller, M.D.
Dr. Faye Feller, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
-100.00%
Mr. Edward E. Koval
Mr. Edward E. Koval
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Robert J. (Bob) Spiegel, M.D.
Dr. Robert J. (Bob) Spiegel, M.D.
Independent Director
Independent Director
188.55K
+3.12%
Dr. Susan M. Molineaux, Ph.D.
Dr. Susan M. Molineaux, Ph.D.
Independent Director
Independent Director
130.53K
--
Mr. Ahmed (Nawawi) Elnawawi
Mr. Ahmed (Nawawi) Elnawawi
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
10.00K
--
Mr. Harout Semerjian
Mr. Harout Semerjian
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Elizabeth G. O'Farrell
Ms. Elizabeth G. O'Farrell
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
--
--
Ms. Shannon T. Odam
Ms. Shannon T. Odam
Chief People Officer, Senior Vice President
Chief People Officer, Senior Vice President
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Dec 7
Updated: Sun, Dec 7
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
9.46%
Deep Track Capital LP
6.44%
BlackRock Institutional Trust Company, N.A.
6.26%
The Vanguard Group, Inc.
5.37%
Vivo Capital, LLC
4.26%
Other
68.20%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
9.46%
Deep Track Capital LP
6.44%
BlackRock Institutional Trust Company, N.A.
6.26%
The Vanguard Group, Inc.
5.37%
Vivo Capital, LLC
4.26%
Other
68.20%
Shareholder Types
Shareholders
Proportion
Hedge Fund
21.93%
Investment Advisor
21.56%
Investment Advisor/Hedge Fund
17.42%
Venture Capital
13.75%
Research Firm
5.90%
Private Equity
0.49%
Bank and Trust
0.37%
Pension Fund
0.21%
Individual Investor
0.11%
Other
18.25%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
550
522.20M
81.85%
-216.12M
2025Q2
556
522.02M
81.82%
-109.82M
2025Q1
562
519.35M
81.62%
-112.90M
2024Q4
542
496.89M
78.04%
-104.32M
2024Q3
507
516.63M
85.72%
-55.02M
2024Q2
483
472.64M
79.70%
-11.19M
2024Q1
446
440.86M
75.14%
+14.56M
2023Q4
419
400.36M
73.45%
-3.49M
2023Q3
411
378.82M
69.84%
+5.68M
2023Q2
402
349.17M
68.60%
+5.31M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
60.38M
9.46%
--
--
Jun 30, 2025
Deep Track Capital LP
43.00M
6.74%
+4.82M
+12.64%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
43.36M
6.8%
+300.24K
+0.70%
Jun 30, 2025
The Vanguard Group, Inc.
35.49M
5.56%
+1.47M
+4.31%
Jun 30, 2025
Vivo Capital, LLC
27.23M
4.27%
--
--
Jun 30, 2025
State Street Investment Management (US)
23.63M
3.7%
-279.92K
-1.17%
Jun 30, 2025
Goldman Sachs & Company, Inc.
9.24M
1.45%
+1.60M
+20.93%
Jun 30, 2025
Soleus Capital Management, L.P.
16.14M
2.53%
+13.74M
+572.50%
Jun 30, 2025
Vestal Point Capital, LP
23.77M
3.73%
+1.77M
+8.04%
Jun 30, 2025
Citadel Advisors LLC
12.04M
1.89%
+5.37M
+80.63%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
1.61%
Virtus LifeSci Biotech Products ETF
1.29%
WisdomTree BioRevolution Fund
0.5%
Invesco NASDAQ Future Gen 200 ETF
0.48%
ALPS Medical Breakthroughs ETF
0.33%
State Street SPDR S&P Biotech ETF
0.3%
Direxion Daily S&P Biotech Bull 3X Shares
0.19%
Inspire Small/Mid Cap ESG ETF
0.18%
ProShares Ultra Nasdaq Biotechnology
0.09%
Invesco Nasdaq Biotechnology ETF
0.08%
View more
iShares Genomics Immunology and Healthcare ETF
Proportion1.61%
Virtus LifeSci Biotech Products ETF
Proportion1.29%
WisdomTree BioRevolution Fund
Proportion0.5%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.48%
ALPS Medical Breakthroughs ETF
Proportion0.33%
State Street SPDR S&P Biotech ETF
Proportion0.3%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.19%
Inspire Small/Mid Cap ESG ETF
Proportion0.18%
ProShares Ultra Nasdaq Biotechnology
Proportion0.09%
Invesco Nasdaq Biotechnology ETF
Proportion0.08%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Geron Corp?
The top five shareholders of Geron Corp are:
RA Capital Management, LP holds 60.38M shares, accounting for 9.46% of the total shares.
Deep Track Capital LP holds 43.00M shares, accounting for 6.74% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 43.36M shares, accounting for 6.80% of the total shares.
The Vanguard Group, Inc. holds 35.49M shares, accounting for 5.56% of the total shares.
Vivo Capital, LLC holds 27.23M shares, accounting for 4.27% of the total shares.
RA Capital Management, LP holds 60.38M shares, accounting for 9.46% of the total shares.
Deep Track Capital LP holds 43.00M shares, accounting for 6.74% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 43.36M shares, accounting for 6.80% of the total shares.
The Vanguard Group, Inc. holds 35.49M shares, accounting for 5.56% of the total shares.
Vivo Capital, LLC holds 27.23M shares, accounting for 4.27% of the total shares.
What are the top three shareholder types of Geron Corp?
The top three shareholder types of Geron Corp are:
RA Capital Management, LP
Deep Track Capital LP
BlackRock Institutional Trust Company, N.A.
RA Capital Management, LP
Deep Track Capital LP
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Geron Corp (GERN)?
As of 2025Q3, 550 institutions hold shares of Geron Corp, with a combined market value of approximately 522.20M, accounting for 81.85% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 0.03%.
What is the biggest source of revenue for Geron Corp?
In --, the -- business generated the highest revenue for Geron Corp, amounting to -- and accounting for --% of total revenue.
